Navigation Links
DUSA Pharmaceuticals Reports Notice of Allowance for Key PDT Device Patent

WILMINGTON, Mass., May 7 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA), a dermatology company that is developing and marketing Levulan® Photodynamic Therapy (PDT), today announced that the United States Patent and Trademark Office has issued a notice of allowance for a key patent related to its proprietary PDT light source, the BLU-U®, Blue Light Photodynamic Therapy Illuminator.  The new patent will have method of treatment claims which cover the use of DUSA's blue light technology and aminolevulinic acid HCL (Levulan®) for the treatment of actinic keratosis as well as the diagnosis and treatment of other disease states such as acne, cancer, psoriasis and photodamaged skin.  The patent also has claims that will cover DUSA's blue light technology in conjunction with its proprietary Levulan® Kerastick® formulation of aminolevulinic acid HCL.  The patent, once issued, which is scheduled to occur on May 25, 2010, will cover our approved Levulan® PDT therapy until June, 2019.  

Robert Doman, DUSA's President and CEO, said, "This patent further strengthens the protection of our Levulan® PDT therapy because the claims cover the use of the BLU-U®, aminolevulinic acid, and our proprietary Levulan Kerastick formulation together to treat actinic keratoses."  Mr. Doman continued, "The successful execution of this intellectual property protection strategy significantly enhances DUSA's patent portfolio for our Levulan® PDT technology.  This provides DUSA with the opportunity to continue on its path of revenue growth and additional time to explore new indications and life cycle management strategies."    

About Levulan® PDT and the BLU-U®

Levulan® Kerastick® for Topical Solution plus blue light illumination using the BLU-U® blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5M treatment visits per year.  DUSA is also in clinical development of its Levulan® PDT technology platform for the broad-area treatment of AKs and the prevention of new non-melanoma skin cancer in chronically immunosuppressed solid organ transplant recipients.

Other Uses of the BLU-U®

DUSA's patented BLU-U® Blue Light Photodynamic Therapy Illuminator also offers effective, non-invasive and pain-free light treatment for moderate inflammatory acne.  Narrow band blue light causes a photodynamic effect within the pilosebaceous gland that kills P. acnes, the bacteria primarily responsible for acne.  BLU-U® treatments can be a primary treatment, an alternative to pharmaceuticals and topicals, or an addition to skin care programs.  In September 2003, DUSA received clearance from the U.S. Food and Drug Administration (FDA) to market the BLU-U® without Levulan® PDT for the treatment of moderate inflammatory acne vulgaris and general dermatologic conditions.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight.  They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms.  They form on the outermost layer of skin and they can range in color from skin toned to reddish brown.  They can also range in size from as small as a pinhead to larger than a quarter.

About Acne

According to the American Academy of Dermatology, acne is the most common skin disorder in the U.S., affecting 40 to 50 million Americans.  There are many types of acne, the most common of which is called acne vulgaris.  Just beneath the surface of the skin lie hundreds of tiny glands called sebaceous glands.  Their function is to collect and excrete the oily substance called sebum, to keep the skin healthy.  However, the tiny pathway for the sebum to escape often becomes clogged and a bacterium called P. acnes grows inside. In a short time, the area swells up and forms a lesion on the skin.  At certain times of life, this process becomes very active, troublesome and hard to control.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® photodynamic therapy (PDT) technology platform, and other dermatology products.  Levulan® PDT is currently approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.  DUSA is researching the use of Levulan® PDT to prevent AKs and squamous cell carcinomas in immunosuppressed solid organ transplant recipients and is supporting research related to oral leukoplakia in collaboration with the National Institutes of Health (NIH).  DUSA also markets other dermatology products, including ClindaReach®.  DUSA is based in Wilmington, Mass.  Please visit our website at

Forward Looking Statements

Except for historical information, this news release contains certain forward-looking statements that represent our current expectations and beliefs concerning future events, and involve certain known and unknown risk and uncertainties.  These forward-looking statements relate to the issuance of a patent and the methods of use and diseases covered by the claims in the patent, the enhancement of the Company's patent portfolio, continued revenue growth, the expected issue date and expiration date of the patent.  These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from future results, performance or achievements expressed or implied by those in the forward-looking statements made in this release.  These factors include, without limitation, actions by regulatory authorities, the status of our patent portfolio, action of third parties, the impact of competitive products, and other risks and uncertainties identified in DUSA's Form 10-K for the year ended December 31, 2009.

SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
2. ADVENTRX Pharmaceuticals Announces Closing of Financing
3. DUSA Pharmaceuticals, Inc.(R) to Host First Quarter 2010 Corporate Highlights and Financial Results Conference Call
4. Trading Halted Today in Questcor Pharmaceuticals Common Stock
5. HealthTronics Enters Into Definitive Merger Agreement With Endo Pharmaceuticals
6. Alexza Pharmaceuticals to Present at The Ninth Annual JMP Securities Research Conference
7. Alexza Pharmaceuticals Files Shelf Registration Statement
8. Sagent Pharmaceuticals and Actavis Enter Into Exclusive U.S. Development, Supply and Marketing Collaboration for a Portfolio of Specialty Injectable Pharmaceutical Products
9. Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of EP-3600 MRI Imaging Agent
10. Reportlinker Adds The Outlook for Pharmaceuticals in Western Europe
11. ISTA Pharmaceuticals to Present at the Ninth Annual JMP Securities Research Conference
Post Your Comments:
(Date:11/30/2015)... Next week, December 2-3, BIOMEDevice San ... co-located events covering the latest in Medtech innovation, Wearable ... draw more than 3,000 design industry professionals to the ... events, combined show floor will host more than 300 ... --> --> BIOMEDevice features suppliers in ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... , Nov. 30, 2015 Nautilus Medical Inc. ... Image Management platform ( ). The release of ... from RSNA 2015 (Radiology Society North America) in ... in the U.S. --> ... that enables access to radiology studies worldwide via a ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... RoamRight, a leading provider of travel insurance and a division of ... to promote family vacations around the world. The television show, which is in ... families about the people and places of the world, all while helping parents navigate ...
(Date:11/30/2015)... ... November 30, 2015 , ... Advocare Orthopedic and Sports ... Led by John Vitolo, M.D., the center offers their patients the highest ... Advocare Orthopedic & Sports Medicine is ready to help their patients return to ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... new study by UPMC and KingMed Diagnostics researchers. Their ... years found that consultation with UPMC pathologists resulted in significantly altered treatment plans ...
(Date:11/30/2015)... ... 30, 2015 , ... The American Society for Clinical Pathology (ASCP) announced today ... 2015. On Nov. 30, ASCP shared its “Give a minute. Get tested. Find a ... the importance of getting tested for HIV. , ASCP has asked members to replace ...
(Date:11/30/2015)... , ... November 30, 2015 , ... An inventor from ... in the womb. "My last baby had high blood pressure due to loud noises," ... to protect their babies from noise pollution as well as radio waves and microwaves." ...
Breaking Medicine News(10 mins):